Zofer

Quick links to important sections

Zofer

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zofer

Quick Facts

Property Description
Active ingredient Ondansetron
Form Tablet (ODT, film-coated), Oral Solution, Injection
Pharmacological class Antiemetic
Origin Synthetic (Carbazolone derivative)

What Type of Medication is Zofer (Ondansetron)?

Zofer is a specialized prescription-only medicine (Rx), primarily classified as an antiemetic designed to counter the symptoms of nausea and vomiting. Its essential identity is derived from its active ingredient, Ondansetron, which places the drug into the highly specific pharmacological class of Selective 5-HT3 receptor antagonists. Ondansetron's efficacy in managing acute emesis is clinically recognized and supported by pharmacological studies. This highly focused classification distinguishes it from older, broad-spectrum antiemetics, defining its general purpose as a key intervention for stabilizing patients experiencing significant discomfort.

Composition, Origin, and Available Pharmaceutical Forms

The core compound, Ondansetron, typically handled as Ondansetron hydrochloride dihydrate, is a synthetic pharmaceutical product belonging chemically to the Carbazolone derivative group. As a monotherapy, Zofer is a single active ingredient preparation developed in multiple high-level pharmaceutical preparations to suit varying clinical needs for both adults and pediatrics. These dosage form(s) include solid presentations, such as rapid-dissolving orally disintegrating tablets (ODT) and film-coated tablets, alongside liquid options like oral solution and injection solution, which permit multiple routes of administration, including Oral, Intravenous (IV), and Intramuscular (IM).

How Zofer Addresses Nausea and Vomiting

Zofer works by executing a physiological action known as 5-HT3 receptor blockade, effectively neutralizing the primary chemical trigger for sickness. This mechanism principle means the medication intercepts the messenger serotonin from binding to its specific receptor sites, which are located both in the digestive tract and centrally in the brain's chemoreceptor trigger zone. By selectively inhibiting these serotonin-mediated signals, the drug provides a reliable means to stabilize the patient and alleviate the physical symptoms of sickness, fulfilling its general purpose as a focused antiemetic agent.

What side effects are possible with Zofer?

The official safety profile for Zofer (ondansetron) organizes possible adverse reactions based on how often they occur and the body system affected, according to regulatory standards (e.g., EMA/FDA).

Frequency-Classified Adverse Reactions

The most frequently observed event in clinical data is headache, which is officially categorized as Very Common. Other effects classified as Common include constipation and a sensation of warmth or flushing. Less common reactions (Uncommon) documented in official sources include seizures, involuntary movement disorders (like dystonia), bradycardia (slowed heart rate), and asymptomatic increases in liver function tests.

System-Organ Classes and Serious Concerns

The label identifies events across several System-Organ Classes, including the Nervous System, Gastrointestinal Disorders, and the Cardiac System. Specific Serious Adverse Reactions are highlighted in regulatory warnings, notably the risk of QT interval prolongation and the associated rare cardiac rhythm disturbance, Torsade de Pointes. The potential for Serotonin syndrome is also documented, particularly when the medicine is used with other serotonergic agents.

Population and Usage Constraints

Safety notes apply to certain patient groups. Individuals with severe hepatic impairment require specific safety consideration. The medicine's use is restricted in those with congenital long QT syndrome due to the cardiac risk. Furthermore, the antiemetic effect may mask signs of progressive ileus or gastric distension following surgical procedures or chemotherapy, a specific limitation noted in the official regulatory documentation.

Overdose and Emergency Response

Overdose and When to Seek Help for Zofer (Ondansetron)

Zofer overdose has been documented in case reports, presenting with specific and severe physiological effects. It is critical to recognize these manifestations and seek immediate medical assistance.

Documented Overdose Presentations and Physiological Effects

Symptoms reported following an overdose of ondansetron include severe and transient neurological and cardiovascular events. These manifestations may include sudden blindness (amaurosis) lasting a few minutes, a vasovagal episode with a temporary second-degree heart block, and hypotension (low blood pressure). Severe constipation has also been described.

In children, cases consistent with Serotonin Syndrome have been reported after inadvertent oral overdoses. Symptoms of this potentially life-threatening syndrome include agitation, somnolence, increased heart rate (tachycardia), high blood pressure (hypertension), fever, myoclonic movements, and seizures.

Immediate Medical Attention

If an overdose is suspected or confirmed, or if any of the severe symptoms described above occur, urgent medical care is required. Individuals with a known congenital long QT syndrome should avoid taking Zofer due to an elevated risk of a potentially fatal heart rhythm disturbance known as Torsade de Pointes. There is no specific antidote for Zofer overdose; therefore, management involves supportive care and treatment of the specific symptoms present.

Therapeutic Uses of Zofer

The core therapeutic use of Zofer (ondansetron) is focused on providing supportive management for severe symptoms of nausea and vomiting across multiple clinical domains. This medication is commonly used to help patients cope more steadily with heightened symptoms related to specific medical procedures.

Zofer is considered relevant for providing symptomatic relief in conditions characterized by periods of heightened symptoms such as sickness associated with highly emetogenic chemotherapy, therapeutic radiation directed at the abdomen, and postoperative nausea and vomiting (PONV) following general anesthesia. Zofer may also assist with managing persistent vomiting in acute cases like pediatric gastroenteritis or for severe hyperemesis gravidarum in pregnancy.

The primary benefit is that the medicine helps maintain a sense of stability when symptoms are more noticeable, and may support the patient's ability to cope with critical medical interventions.


Quick Fact: Relief for Acute Nausea and Vomiting
Therapeutic Role: Supportive management of acute and delayed symptoms.
Patient Benefit: Contributes to improved comfort and assists with maintaining functional stability during symptomatic episodes.
Primary Contexts: Oncology, Surgical Recovery, Acute Vomiting Crises.

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

Zofer (ondansetron) is subject to strict eligibility rules based on regulatory requirements. These rules define which populations may use the medicine and which are excluded or require conditional use.

Classification Who Must Not Use (Contraindicated)
Absolute Contraindications Patients with known hypersensitivity to ondansetron or any component of the formulation. Concomitant use of apomorphine (due to risk of profound hypotension). Patients with congenital long QT syndrome (due to QTc prolongation risk).
Classification Conditional or Restricted Use
Severe Hepatic Impairment The total daily dose must not exceed 8 mg (oral or intravenous) due to reduced drug clearance.
Pregnancy/Lactation Not recommended during the first trimester of pregnancy due to a potential small increased risk of orofacial malformations. Breastfeeding is not recommended while receiving treatment.

Age-Related Eligibility:

  • Use is established for pediatric patients starting from 6 months of age for chemotherapy-induced nausea and vomiting (CINV) and 1 month of age for intravenous prevention of postoperative nausea and vomiting (PONV).
  • Renal impairment does not require a change in dosage or frequency. The official profile defines eligibility through mandatory exclusions for specific cardiac and hypersensitivity conditions, and through dose limitations for severe liver dysfunction, ensuring the medicine is only used where the benefit outweighs officially documented risks to specific patient groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions with Zofer (ondansetron) that are officially documented in government regulatory labeling, including potential pharmacokinetic alterations and pharmacodynamic risks.

Classification Interacting Agents / Conditions Official Regulatory Statement
Contraindicated Combination Apomorphine Co-administration is strictly prohibited due to documented reports of profound hypotension and loss of consciousness [FDA/EMA].
Pharmacokinetic (Decreased Exposure) Phenytoin, Carbamazepine, Rifampin (potent CYP3A4 inducers) These agents significantly increase ondansetron clearance, resulting in decreased ondansetron blood concentrations [FDA Label].
Pharmacokinetic (Increased Exposure) Aprepitant (moderate CYP3A4 inhibitor) Co-administration causes an approximate 15% increase in ondansetron exposure (Area Under the Curve) [Regulatory Source].
Pharmacodynamic (Additive Risk) Serotonergic Drugs (e.g., SSRIs, SNRIs, Tramadol, Lithium) Concurrent use is associated with a risk of Serotonin Syndrome (additive neurological effects) [FDA/SmPC].
Pharmacodynamic (Additive Cardiac Risk) Drugs that Prolong the QT Interval (e.g., certain antiarrhythmics, antibiotics) Co-administration may increase the risk of QT interval prolongation and the potential for Torsade de Pointes [FDA/SmPC].
Population-Specific Change Severe Renal Impairment (creatinine clearance < 30 mL/min) Mean plasma clearance of ondansetron is officially documented as being reduced by approximately 41% [FDA Label].

No timing separation rules (e.g., “administer X hours apart”) are listed in official labeling. The profile is defined by a mandatory exclusion (apomorphine) and the requirement to monitor for increased risk when co-administering substances that affect the drug's metabolic clearance or that share additive cardiac/neurological effects.

Mechanism of Action

The physiological activity of Zofer is rooted in the modulation of emetic signaling pathways through a highly specific competitive antagonism of the 5-HT₃ receptors. These receptors function as ligand-gated ion channels for the neurotransmitter serotonin (5-HT). Zofer acts at two primary locations: peripherally on vagal afferent neurons within the gastrointestinal tract and centrally within the brain's Chemoreceptor Trigger Zone (CTZ).

By physically binding to the receptor sites, the drug prevents 5-HT from activating the ion channels. This molecular blockade interrupts the propagation of the nerve signal. The dual action—reducing the transmission of excessive mediator activity from the gut and inhibiting the central signal initiation in the CTZ—influences the magnitude of the physiological response. This modulation of the emetic reflex arc results from the reduction of signaling within the targeted neurochemical pathways.

Dosage and Administration Information

How to Use Zofer

The administration of Zofer (ondansetron) is governed by the clinical context and the specific pharmaceutical form used. The medicine is primarily employed as a prophylactic agent, meaning its use is timed to occur before the anticipated event, such as chemotherapy, radiation, or surgery.


Official Routes and Timing

Zofer is administered via Oral (tablets, solution, or ODT), Intravenous (IV), and Intramuscular (IM) routes. For prevention of highly emetogenic chemotherapy-induced nausea and vomiting (CINV), the oral regimen is a single 24 mg dose administered 30 minutes prior to the start of chemotherapy. For IV use in CINV, the regimen is typically multiple weight-based doses, with the maximum single IV dose not exceeding 16 mg.


Administration Requirements and Schedule

Context Administration Detail
Oral Timing Administered 30 minutes to 2 hours before the emetogenic event.
IV Preparation Must be diluted in appropriate solutions (e.g., 0.9% Sodium Chloride) for CINV prophylaxis.
Dose Continuation The schedule often continues for 1 to 2 days, or up to 5 days after the end of the emetogenic course for delayed symptom management.

Population-Specific Use

Dose adjustments are necessary for certain patient populations. For patients with severe hepatic impairment, the total daily dose must not exceed 8 mg, regardless of the route of administration. For pediatric patients (aged 6 months or older for CINV), dosing is determined based on their Body Surface Area or weight in kilograms. Generally, no dose adjustment is required for older adults or individuals with renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the published research that evaluated the compound, Zofer (ondansetron), and its activity. This information is purely descriptive of the studies' findings and is not intended as an interpretation or recommendation for use.


Activity Mechanism Studies

Research investigated the compound's mechanism of action, which involves the selective antagonism of the 5-HT₃ receptor—a serotonin receptor. This activity is believed to interrupt the signaling pathways that lead to nausea and vomiting in both the gastrointestinal tract and the central nervous system. Studies have compared this activity with the actions of older antiemetic compounds.

Clinical Trial Information

Major Study Data

The effectiveness of the compound has been established across several randomized, placebo-controlled clinical trials focusing on its approved indications: chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).

  • CINV: Clinical studies consistently found that use of the compound was associated with control of CINV in adult cancer patients, particularly in the acute phase following chemotherapy.
  • PONV: Research also reported findings demonstrating the compound's utility for prevention and management in the postoperative setting.

Research in Specific Populations

Studies have been conducted to evaluate the compound in various populations, including:

  • Pediatrics: The compound's safety profile and effectiveness in managing CINV have been studied in children aged six months and older. Research suggests the side effect profile in children is comparable to that seen in adults.
  • Hepatic Impairment: Research suggests that in patients with severe hepatic impairment, the body's clearance of the compound is reduced, which may necessitate caution during use.

Safety and Tolerability Research

Research has explored the compound's safety profile. A key area of study is the potential for QT interval prolongation, a change in the heart's electrical rhythm, particularly when administered intravenously or at higher doses. Other commonly reported side effects across studies include headache, constipation, and diarrhea. Studies have also investigated potential drug-drug interactions with other medications that affect serotonin or the QT interval.

Key Studies & References

  1. Antiemetics, Selective 5-HT3 Antagonists - StatPearls (Ondansetron mechanism and general efficacy)
  2. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV Guidelines)

Frequently Asked Questions (FAQ)

Common questions about Zofer (FAQ)


Q: Is Zofer considered a strong anti-nausea medication?

Regulatory reviews and clinical studies describe Zofer's active ingredient, ondansetron, as a key intervention that addresses acute nausea and vomiting, particularly that related to chemotherapy and surgical procedures. Its specialized mechanism of action sets it apart from older antiemetics.


Q: How quickly does Zofer start working after taking it?

According to the official product information, the medicine typically begins to work relatively quickly. The effect generally starts within 30 minutes after taking an oral dose.


Q: How long does the effect of a dose of Zofer usually last?

The specific duration of the therapeutic effect from a single dose is not stated as a fixed time in the regulatory documents. However, the therapeutic use described in official dosage schedules often involves repeated administration, consistent with the drug's duration of effect.


Q: Are there specific food or drink restrictions while using Zofer?

Official regulatory documents state that oral forms of the medication can be taken with or without food. There are no specific restrictions for typical food or drink listed in the prescribing information.


Q: What is the difference between Zofer and other motion sickness tablets?

Zofer is a specialized antiemetic classified as a selective 5 -HT3 receptor antagonist. Most common motion sickness tablets belong to a different drug class (e.g., antihistamines). Zofer is officially indicated for nausea and vomiting related to medical treatments, such as chemotherapy or surgery, and its approved uses are specific.


Q: Is Zofer related to or similar to Dramamine?

Zofer is not related to or similar to Dramamine (dimenhydrinate). They belong to different drug classes and work through distinct mechanisms. Zofer targets serotonin receptors, while Dramamine works as an antihistamine.


Q: Does Zofer cause drowsiness or make you feel sleepy?

Regulatory documents state that drowsiness or fatigue is a reported adverse reaction. This is classified as common in some clinical trial patient groups.


Q: Can Zofer affect your mood or cause anxiety?

Official clinical trial data indicates that anxiety and agitation have been noted as potential side effects. The official profile addresses these concerns.


Q: Does Zofer interact with supplements like St. John's Wort?

Official guidance indicates that St. John's Wort can interact with Zofer. This supplement may affect the rate at which Zofer is processed by the body, which could influence the drug's concentrations. Furthermore, because St. John's Wort also affects serotonin levels, taking it with Zofer could increase the risk of Serotonin Syndrome.


Q: Are there studies about Zofer's use for treating morning sickness?

While the drug's approved indications are specific (chemotherapy, radiation, and surgery), its active ingredient has been reviewed in official clinical guidelines for severe, refractory nausea and vomiting of pregnancy (known as hyperemesis gravidarum). This indicates that the topic has been studied and considered in clinical contexts.


Q: Does Zofer affect blood pressure?

Low blood pressure (hypotension) has been reported in the context of serious adverse events like allergic reactions. The risk of low blood pressure is specifically documented when the drug is co-administered with Apomorphine.


Q: Can Zofer be taken on an empty stomach?

Yes, according to the official product information, oral forms of the medication can be taken with or without food.


Q: Is Zofer related to or the same as the drug metoclopramide?

Zofer is not the same as metoclopramide. Zofer is a selective 5 -HT3 receptor antagonist, while metoclopramide acts as a D2 receptor antagonist. These are distinct drug classes that work through different chemical pathways in the body.


Q: Are there any reported cases of dependence or addiction with Zofer?

The FDA prescribing information includes a specific section dedicated to reviewing the topic of Drug Abuse and Dependence for this medication. This indicates that the subject has been formally reviewed by regulatory bodies.


Q: What are the common signs of taking too much Zofer?

Signs described in the official documents include severe constipation, low blood pressure (hypotension), fainting, and sudden changes in vision or temporary blindness. The official product information addresses the potential for overdosage.


Q: Does Zofer have different brand names I might recognize?

Yes, Zofer is one brand name for the active ingredient, ondansetron. A very common brand name that you might recognize, and which is frequently referenced in regulatory communications, is Zofran.


Q: Why does Zofer sometimes make people feel lightheaded?

Lightheadedness is a reported side effect. It is also listed as a symptom that can be associated with the officially documented cardiac risk (such as QT prolongation), a serious adverse reaction.


Q: Is the research on Zofer considered conclusive by regulatory bodies?

The effectiveness of Zofer for its approved uses is established by clinical trials and regulatory approval. However, regulatory bodies maintain ongoing surveillance of safety and may require labeling updates as new information emerges.


Q: Can Zofer cause dizziness, and is that a common side effect?

Official clinical trial data shows that dizziness is a reported side effect. This is classified as a common occurrence in some patient groups.


Q: Does Zofer interact with alcohol, and what does official guidance say?

Official drug information states there are no known direct chemical interactions between Zofer and alcohol. However, consumption of alcohol may be advised against because alcohol can worsen common side effects and the underlying conditions that cause nausea and vomiting.


Q: Can Zofer be used for nausea that isn't caused by a medical treatment?

The official regulatory indications for Zofer are highly specific, covering the prevention of nausea and vomiting associated with cancer chemotherapy, radiation therapy, and surgery. It is not officially indicated for general or routine non-treatment-related nausea.

How should Zofer be stored and disposed of?

How to Store and Dispose of Zofer (Ondansetron)

Official regulatory documents define specific storage and handling requirements for Zofer to maintain product stability.


Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store most forms between 2 C and 30 C (36 F and 86 F). Do not freeze liquid formulations.
Light Protection The Injection solution must be protected from light.
Child Safety Must be kept out of the sight and reach of children.
Handling ODT tablets must not be removed from the blister packaging until immediately prior to use. Diluted injection solutions must be used within 24 hours.

Disposal Instructions

Unused or expired Zofer must be disposed of in accordance with local procedures for pharmaceutical waste. Unless otherwise instructed by an official take-back program, the medication should not be disposed of via household wastewater (e.g., pouring down the sink).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zofer found in:

A-Z Index: